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Background
Psychotropics are overprescribed for adults with intellectual
disabilities; there are few studies in children and young people.
Aims
To investigate antipsychotic and antidepressant prescribing in
children and young people with and without intellectual disabil-
ities, and prescribing trends.
Method
Scotland’s annual Pupil Census, which identifies pupils with and
without intellectual disabilities, was record-linked to the
Prescribing Information System. Antidepressant and anti-
psychotic data were extracted. Logistic regression was used to
analyse prescribing between 2010 and 2013.
Results
Of the 704 297 pupils, 16 142 (2.29%) had a record of intellectual
disabilities. Antipsychotic and antidepressant use increased over
time, and was higher in older pupils; antipsychotic use was
higher in boys, and antidepressant use was higher in girls.
Overall, antipsychotics were prescribed to 281 (1.74%) pupils
with intellectual disabilities and 802 (0.12%) without (adjusted
odds ratio 16.85, 95% CI 15.29–18.56). The higher use among
those with intellectual disabilities fell each year (adjusted odds
ratio 20.19 in 2010 v. 14.24 in 2013). Overall, 191 (1.18%) pupils
with intellectual disabilities and 4561 (0.66%) without were pre-
scribed antidepressants (adjusted odds ratio 2.28, 95% CI 2.03–
2.56). The difference decreased each year (adjusted odds ratio
3.10 in 2010 v. 2.02 in 2013).
Conclusions
Significantly more pupils with intellectual disabilities are pre-
scribed antipsychotics and antidepressants than are other
pupils. Prescribing overall increased over time, but less so for
pupils with intellectual disabilities; either they are not receiving
the same treatment advances as other pupils, or possible over-
prescribing in the past is changing. More longitudinal data are
required.
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Adults with intellectual disabilities are overprescribed psychotropic
prescriptions,1,2, but surprisingly few studies have focussed on chil-
dren and young people. Children and young people with intellectual
disabilities are more likely to experience psychiatric disorders than
those without intellectual disabilities.3–5 However, few children or
young people experience psychosis, as the peak onset in males is at
age 20–24 years and, for females, a less prominent peak occurs at
20–24 years, followed by another at >35 years.6 However, antipsycho-
tics are also prescribed ‘off-label’ in children and young people with
intellectual disabilities with problem behaviours, such as aggression,
disruptive behaviour or hyperactivity.7 Although there is some evi-
dence of effectiveness, more so for risperidone, the quality of evidence
is low, and side-effects are common, including for atypical antipsy-
chotics.8–11 Indeed, it has been suggested that antipsychotic side-
effects occur more commonly in children with intellectual disabilities
than in other children, and they have difficulty reporting them;3 it has
also been suggested that prescribing antipsychotics to children with
problem behaviours is maltreatment.12 The UK National Institute
for Health and Care Excellence and other guidelines recommend
that antipsychotic drugs should be reduced or discontinued in
people with intellectual disabilities who are not experiencing psych-
osis,13,14 and that use is considered only when psychological or
other interventions alone do not produce change within an agreed
time, or risk is very severe.15 Similarly, systematic reviews of
antidepressant prescribing in this population have also deemed
studies to be low quality, with small sample sizes,16 and most antide-
pressants are contraindicated in children and youth, with suicidal
ideation being a side-effect. Despite these cautions, there has been
little study of the rates of prescription of antipsychotics and antide-
pressants in children with intellectual disabilities, or any changes
over time. A review of general practice records in England reported
that 2.4% with intellectual disabilities aged ≤18 years were prescribed
antipsychotics and 1.2% were prescribed antidepressants between
2009 and 2012, but the authors did not provide longitudinal data.1
A Taiwanese study reported an increase in out-patient clinic psycho-
tropic prescribing between 1997 and 2007 of 16.67% for children with
intellectual disabilities, and 14.69% for youth with intellectual disabil-
ities.17 For antidepressant prescribing, the increases were 46.05% for
childrenwith intellectual disabilities and 124.19% for youthwith intel-
lectual disabilities, but the sample was not population-based.17
Aims
This study aimed to investigate the use of antipsychotic and anti-
depressant prescribing to the whole population of children and
young people with intellectual disabilities in Scotland, compared
with those without intellectual disabilities, and to investigate
trends in prescribing over a 4-year period.
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Method
Approvals
This study was approval by the National Health Service (NHS)
National Services Scotland Public Benefit and Privacy
Panel (Application number 1617-0259). Individual participant
consent was not required.
Data sources and linkage
In Scotland, a Pupil Census is conducted in September each year. It
collects information on all children and young people attending
local authority primary, secondary and special schools in Scotland,
or children and young people with local authority-funded placements
in alternative schools. This includes 95% of all children and young
people in Scotland.We can identify no reason to suspect that children
with intellectual disabilities would be more likely than other children
to be home-educated or have parents paying school fees for their edu-
cation at a public school. In 2010, 35.8% of pupils with intellectual
disabilities attended special schools, and 64.2% attended mainstream
schools; in 2011, these figures were 29.1% and 70.9%; in 2012, they
were 27.7% and 72.4% and in 2013, they were 29.0% and 71.0%,
respectively. The information collected in the Pupil Census includes
whether the child/young person has a record of additional support
needs, and the type of additional support needs including intellectual
disabilities. The types of additional support needs recorded differen-
tiate between intellectual disabilities and specific learning disabilities
such as dyslexia and dyscalculia. Under the Education (Additional
Support for Learning) (Scotland) Act 2004 (as amended), education
authorities have a statutory requirement to identify and provide for
the additional support needs of children and young people. The
assessment includes informal observations by teachers, and more
formal assessments from education, medical or psychological profes-
sionals (educational psychology, NHS community child health teams
and clinical genetics services are available throughout Scotland, to
provide these and other assessments). In the Pupil Census, teachers
record the additional support needs identified from these assess-
ments. It is held by the Scottish Exchange of Education Data. We
used data from the four censuses conducted in 2010–2013, to identify
children and young people with and without intellectual disabilities,
aged up to 19 years. Records for each year were only included in the
analysis if the child was aged 4 years or older in that particular year.
We then used individual record linkage based on probabilistic record
matching (on date of birth, gender and postcode) to the Community
Health Index (CHI; Scotland’s list of all unique patient identifiers).
We excluded non-singleton births (identified from maternity
records), as names were not used to link the pupil records to the
CHI, and therefore we could not decipher whether the correct child
had linked. We excluded any records with duplicate pupil records
or where the linkage was tied with another pupil. CHI was used to
link the Pupil Census data at an individual level to prescribing data
for each child; it did not provide any additional information for the
study. Using the CHI, we then linked the Pupil Census data to
Scotland’s Prescribing Information System (PIS) to investigate pre-
scriptions encashed over 2010–2013. PIS records all medicines that
are prescribed and dispensed in the community in Scotland, or
issued in hospitals and dispensed in the community, and prescrip-
tions written in Scotland that were dispensed elsewhere in the UK,
and includes coding of the prescriptions by British National
Formulary codes. Only pupils with intellectual disabilities recorded
in at least two different school years were included in the intellectual
disabilities group, to reduce potential bias as a result of miscoding.
Pupils who were included in at least two pupil censuses over the
study period and had no record of intellectual disabilities were used
as the comparison group. Antidepressant and antipsychotic prescrib-
ing data were extracted from the PIS for the two groups, for each of
the 4 years (2010–2013). Prescription codes for each year were deter-
mined using the British National Formulary chapter 4, section code
402 for antipsychotics and 403 for antidepressants.18
Statistical analyses
Participant characteristics were summarised for pupils with and
without intellectual disabilities, using counts and percentages for
categorical data and mean and s.d. for age. Prescribing of antipsy-
chotics and antidepressants at any time during 2010–2013 was sum-
marised for pupils with and without intellectual disabilities by age
group and gender, using counts and percentages. Prescribing was
then compared between pupils with and without intellectual disabil-
ities, using univariate logistic regression models to produce odds
ratios and corresponding 95% confidence intervals. The models
were run univariately and then adjusted for age, gender and
census year. These models were then extended again to include an
interaction term between census year and population (intellectual
disabilities or without intellectual disabilities), to assess whether
there was a statistically significant difference in prescribing
between census years for the different populations. If a statistically
significant interaction was found, then subgroup analysis was per-
formed by individual census years 2010 to 2013, and by population
group (intellectual disabilities or without intellectual disabilities).
All analyses were performed with R version 3.5.0 for Windows
(R Core team, Vienna, Austria; see https://www.R-project.org/).
Results
Participant characteristics
The final linked data-set contained records for 704 297 pupils aged
between 4 and 19 years, who had been included in at least two cen-
suses. Of these, 16 142 (2.29%) had at least two records of additional
support needs owing to intellectual disabilities, and 688 155
(97.71%) had no record of intellectual disabilities. The mean age
of the pupils with intellectual disabilities was 9.53 years (s.d. 3.55),
and the mean age of the pupils without intellectual disabilities was
9.22 years (s.d. 3.96). As expected, there were more male than
female pupils with intellectual disabilities,19 and an almost even
split in gender for the population without intellectual disabilities
(Table 1).
Antipsychotic prescribing
Antipsychotics were prescribed at some point from 2010 to 2013 for
281 (1.74%) of the pupils with intellectual disabilities and 802
(0.12%) of the pupils without intellectual disabilities (Table 2).
More male than female pupils were prescribed antipsychotics in
Table 1 Characteristics of pupils at the year of first inclusion in a
census
Intellectual disabilities No intellectual disabilities
n
(n = 16 142) %
n
(n = 688 155) %
Gender
Male 10 424 64.6% 347 539 50.5%
Female 5718 35.4% 340 616 49.5%
Age in 2010 (years)
<4 554 3.4% 56 797 8.3%
4–11 10 292 63.8% 398 532 57.9%
12–16 5201 32.2% 231 912 33.7%
17–19 95 0.6% 914 0.1%
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both populations. The unadjusted odds ratio of the association of
intellectual disabilities with antipsychotic prescribing was 18.21
(95% CI 16.54–20.04).
Antipsychotics were prescribed to pupils with intellectual dis-
abilities at rates of 0.85% in 2010, 1.02% in 2011, 0.90% in 2012
and 0.99% in 2013; compared with rates in pupils without intellec-
tual disabilities of 0.04% in 2010, 0.05% in 2011, 0.05% in 2012 and
0.06% in 2013. Table 3 shows the logistic regression results, which
indicated an odds ratio of 16.85 (95% CI 15.29–18.56) of intellectual
disabilities being associated with antipsychotic prescribing, when
adjusted for census year, age and gender. Older age, male gender
and later census year were also associated with an increase in anti-
psychotic prescribing (Table 3). The interaction term between
population (intellectual disabilities or without intellectual disabil-
ities) and census year was also significant (P = 0.002). Hence, sub-
group analyses were conducted, and we found that the adjusted
association of intellectual disabilities with being prescribed antipsy-
chotics showed a gradient of falling over time (odds ratios of 20.19
(95% CI 16.34–24.84) in 2010, 18.84 (95% CI 15.57–22.70) in 2011,
15.55 (95%CI 12.75–18.86) in 2012 and 14.24 (95%CI 11.80–17.10)
in 2013). In the subgroup analyses for the association of census year
on antipsychotic prescribing in the population with intellectual dis-
abilities, referenced to 2010, there was also a gradient showing
increase over time (adjusted odds ratios of 1.18 (95% CI 0.94–
1.49) for 2011, 1.27 (95% CI 1.00–1.61) for 2012 and 1.80 (95%
CI 1.42–2.28) for 2013). For the population without intellectual dis-
abilities, there was an increase over time; corresponding adjusted
odds ratios were 1.29 (95% CI 1.10–1.52) for 2011, 1.68 (95% CI
1.43–1.98) for 2012 and 2.62 (95% CI 2.24–3.08) for 2013. These
subgroup analyses show that the increase in prescribing previously
observed for year remains in both populations, most clearly for
those without intellectual disabilities who have a greater increase
with year.
Antidepressant prescribing
Antidepressants were prescribed at some point in 2010–2013 to 191
(1.18%) of the pupils with intellectual disabilities, and 4561 (0.66%)
of the pupils without intellectual disabilities (Table 2). More female
than male pupils were prescribed antidepressants in both
populations. The unadjusted odds ratio of the association of intel-
lectual disabilities with antidepressant prescribing was 2.05 (95%
CI 1.82–2.29).
Antidepressants were prescribed to pupils with intellectual dis-
abilities at rates of 0.29% in 2010, 0.47% in 2011, 0.51% in 2012
and 0.60% in 2013; compared with rates in the pupils without intel-
lectual disabilities of 0.10% in 2010, 0.22% in 2011, 0.25% in 2012
and 0.31% in 2013. The logistic regression (Table 4), to determine
the association between intellectual disabilities and antidepressant
prescribing, found that pupils with intellectual disabilities were over
twice as likely as other pupils to be prescribed antidepressants when
adjusted for census year, age and gender. Older age, female gender
and later census years were also associated with higher odds of anti-
depressant prescribing (Table 4). The interaction term between popu-
lation (intellectual disabilities or without intellectual disabilities) and
census year was significant (P = 0.007). Hence, subgroup analyses
were conducted, and we found that the adjusted association of intel-
lectual disabilities with being prescribed antidepressants showed a
gradient of falling over time (odds ratios of 3.10 (95% CI 2.27–4.12)
in 2010, 2.48 (95% CI 1.95–3.11) in 2011, 2.12 (95% CI 1.69–2.64)
in 2012 and 2.02 (95% CI 1.64–2.47) in 2013). Similar to the anti-
psychotic results, this indicates that the increase in prescribing for
the intellectual disabilities population overall remained across all
years of the census, although the scale of the increased odds
reduced by year. In the subgroup analyses exploring the association
of census year on antidepressant prescribing in the intellectual disabil-
ities population, referenced to census year 2010, there was also a gra-
dient showing increase over time (adjusted odds ratios of 1.61 (95%
CI 1.12–2.33) for 2011, 2.27 (95% CI 1.59–3.29) for 2012 and 3.82
(95% CI 2.68–5.51) for 2013). For the population without intellectual
disabilities, there was an increase over time; corresponding adjusted
odds ratios were 2.14 (95% CI 1.96–2.34) for 2011, 3.95 (95% CI
3.61–4.31) for 2012 and 7.76 (95% CI 7.10–8.49) for 2013. These sub-
group analyses show that the increase in prescribing previously
observed for year also remains in both populations, and is greater
for those without intellectual disabilities.
Table 2 Antipsychotic and antidepressant prescribing in the period 2010–2013 in pupils with and without intellectual disabilities
Antipsychotics Antidepressants
Intellectual disabilities, n (%) Without intellectual disabilities, n (%) Intellectual disabilities, n (%) Without intellectual disabilities, n (%)
All 281/16 142 (1.74%) 802/688 155 (0.12%) 191/16 142 (1.18%) 4561/688 155 (0.66%)
Gender
Male 204/10 424 (1.96%) 499/347 539 (0.14%) 111/10 424 (1.06%) 1424/347 539 (0.41%)
Female 77/5718 (1.35%) 303/340 616 (0.09%) 80/5718 (1.4%) 3137/340 616 (0.92%)
Age in 2010 (years)
4–11 120/10 292 (1.17%) 282/398 532 (0.07%) 55/10 292 (0.53%) 819/398 532 (0.21%)
12–16 150/5201 (2.88%) 505/231 912 (0.22%) 131/5201 (2.52%) 3693/231 912 (1.59%)
17–19 8/95 (8.42%) 5/914 (0.55%) <5/95 (<5.22%) 30/94 (3.28%)
Table 3 Logistic regression to determine the association of intellectual disabilities with antipsychotic prescribing











Intellectual disabilities 18.21 16.54–20.04 <0.001 16.85 15.29–18.56 <0.001
Age (per 1-yr increase) 1.29 1.27–1.31 <0.001
Female gender 0.53 0.48–0.58 <0.001
Census year (per 1-yr increase) 1.32 1.27–1.38 <0.001
Interaction of census year and population (with or
without intellectual disabilities)
0.002
a. Model for population effect, adjusted for age, gender and census year.
b. Interaction between census year and population added to above adjusted model.
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Discussion
Principal findings and interpretation
As far as we are aware, this is the first study of antipsychotic and
antidepressant prescribing, and trends in prescribing, in a country’s
whole population of children and young people with intellectual dis-
abilities, in comparison with those without intellectual disabilities.
Over the study period, 1.74% of pupils with intellectual disabilities
received antipsychotics and 1.18% received antidepressants.
Compared with their peers, their odds of receiving the drugs were
16 and 2, respectively, after adjusting for potential confounders.
Psychotropic prescribing in children and young people must be
undertaken cautiously after other options have been exhausted,
but it does play a role in certain situations. The relative difference
between them and their peers fell over time, but this was because
of increased use of antipsychotics and antidepressants by their
peers, not decreased use among children with intellectual disabil-
ities. These apparent changes in antipsychotic, and particularly anti-
depressant use over a 4-year period highlight the need for further
longitudinal studies, especially as there have been no other popula-
tion-based longitudinal studies of psychotropic drug use conducted
with children with intellectual disabilities.
Comparison with previous literature
Our finding of 1.74% of pupils with intellectual disabilities being
prescribed antipsychotics in 2010–2013 compares with the higher
rate reported in England of 2.4% for the similar period of 2009–
2012; however, our finding of 1.18% for antidepressants is similar
to the 1.2% reported in England.1 We found that antipsychotic pre-
scribing had increased, which was also reported in a study in Wales,
but for a non-comparable population as it included children and
youth with autism together with those with intellectual disabilities.20
The Taiwanese study reported considerable increase in prescribing
of psychotropics, particularly antidepressants, but included only
attenders at out-patient clinics, and has a different healthcare
system to that in the UK, so is not comparable with our study.17
Additionally, in a study comparing 16 countries, Taiwan was
shown to have the highest antipsychotic prescribing rates for
general population children and young people of all the countries,
so prescribing practices may differ from the UK.21 A small USA
study is also not directly comparable with ours as they reported
on children with comorbid intellectual disabilities andmental disor-
ders; unlike our study, they found no change in antipsychotic use
between 2007–2011.22 Psychotropic prescribing for children and
young people has increased over time in the general population,
particularly in Europe, the USA and Canada.23 In our study, we
have shown that the extent of increase is less in pupils with intellec-
tual disabilities than in pupils without intellectual disabilities.
Higher prescribing rates in youth rather than childhood mirrors
the pattern of emerging mental disorders with age, and may be
related to the greater challenges for families in managing aggressive
problem behaviour in adolescents rather than smaller children.
Higher prescribing rates of antipsychotics in males and antidepres-
sants in females follow the same pattern as that seen in the general
population,23 and in the English study of children and young people
with intellectual disabilities.1
Strengths and limitations
Our study included the whole country, and the pupil census has
approximately 95% coverage of school pupils. The data were longi-
tudinal. Scotland is a high-income country, provides additional
support in school to children with intellectual disabilities (which
is advantageous to children with this diagnosis) and has compre-
hensive multidisciplinary community paediatric and genetic ser-
vices, so few children with intellectual disabilities would not be
identified. However, there may still be some recording errors in
the census, hence we required the children to have a record of intel-
lectual disabilities on at least two occasions to be included in the
intellectual disabilities population. We did not have data on the
severity of pupil’s intellectual disabilities. We did not have data on
the mental health of children and young people. Additionally, we
were unable to access data on the 5% of children and young
people not in school. Further, the pupil census is focussed on infor-
mation about the pupils, not individual data about their parents or
households, and so we have no contextual information that might
have been relevant on any associations with, for example, parental
mental health, parental income, parental occupation or parental
educational attainments.
Implications
Children and young people with intellectual disabilities are signifi-
cantly more likely to be prescribed antipsychotics and antidepres-
sants than children and young people without intellectual
disabilities. Psychotropic prescribing for children and young
people is increasing, but at a lesser rate for those with intellectual
disabilities compared with those without. We do not know if that
suggests that children and young people with intellectual disabilities
are not receiving the same treatment advances (i.e. better identifica-
tion of mental ill-health and more prescribing, appropriately) over
time as children and young people without intellectual disabilities,
or if children and young people with intellectual disabilities were
being overprescribed psychotropics in the past and this was
addressed to an extent in this time period, or if overprescribing is
increasing in children and young people without intellectual disabil-
ities. It is important that prescribers in psychiatric services are vigi-
lant to these possibilities, and prescribe when beneficial to the child,
using the lowest therapeutic dose that is effective for each child, and
withdrawing psychotropic drugs when there is no clear indication
or benefit. Longitudinal observation is clearly important to quantify
and understand these prescribing trends, and future research should
Table 4 Logistic regression to determine the association of intellectual disabilities with antidepressant prescribing











Intellectual disabilities 2.05 1.82–2.29 <0.001 2.28 2.03–2.56 <0.001
Age (per 1-yr increase) 1.59 1.57–1.61 <0.001
Female gender 1.99 1.89–2.10 <0.001
Year (per 1-yr increase) 1.93 1.88–1.98 <0.001
Interaction of census year and population (with or
without intellectual disabilities)
0.007
a. Model for population effect, adjusted for age, gender and census year.
b. Interaction between census year and population added to above adjusted model.
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investigate longitudinal prescribing in children and adolescents
with intellectual disabilities in relation to mental health diagnoses,
and adverse health outcomes.
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